GKOS GLAUKOS Corp

  1. Stocks
  2. Healthcare
  3. NYSE: GKOS

Price (delayed)

$54.85

Market cap

$2.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.92

Enterprise value

$2.94B

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, ...

Highlights
The revenue has grown by 2.2% from the previous quarter
The quick ratio has contracted by 30% YoY but it has grown by 6% from the previous quarter
The company's gross profit fell by 3.3% YoY but it rose by 2.4% QoQ
GLAUKOS's EPS has decreased by 40% from the previous quarter
GLAUKOS's net income has decreased by 40% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.glaukos.com
Peers: BSX ICUI IART ATRC

Key stats

What are the main financial stats of GKOS
Market
Shares outstanding
48.21M
Market cap
$2.64B
Enterprise value
$2.94B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.16
Price to sales (P/S)
9.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.18
Earnings
Revenue
$289.08M
EBIT
-$124.65M
EBITDA
-$88.24M
Free cash flow
-$104.09M
Per share
EPS
-$2.92
Free cash flow per share
-$2.17
Book value per share
$10.62
Revenue per share
$6.04
TBVPS
$12.63
Balance sheet
Total assets
$972.59M
Total liabilities
$464.08M
Debt
$383.24M
Equity
$508.51M
Working capital
$353.49M
Liquidity
Debt to equity
0.75
Current ratio
6.67
Quick ratio
5.81
Net debt/EBITDA
-3.4
Margins
EBITDA margin
-30.5%
Gross margin
75.8%
Net margin
-48.2%
Operating margin
-43.3%
Efficiency
Return on assets
-13.9%
Return on equity
-25.9%
Return on invested capital
-14.9%
Return on capital employed
-13.7%
Return on sales
-43.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GKOS stock price

How has the GLAUKOS stock price performed over time
Intraday
-0.69%
1 week
-6.54%
1 month
16.98%
1 year
34.93%
YTD
25.57%
QTD
9.48%

Financial performance

How have GLAUKOS's revenue and profit performed over time
Revenue
$289.08M
Gross profit
$219.09M
Operating income
-$125.1M
Net income
-$139.2M
Gross margin
75.8%
Net margin
-48.2%
GKOS's operating income has shrunk by 52% QoQ
The company's operating margin fell by 49% QoQ
GLAUKOS's net income has decreased by 40% QoQ
The net margin has decreased by 37% QoQ

Growth

What is GLAUKOS's growth rate over time

Valuation

What is GLAUKOS stock price valuation
P/E
N/A
P/B
5.16
P/S
9.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.18
GLAUKOS's EPS has decreased by 40% from the previous quarter
The price to book (P/B) is 24% less than the 5-year quarterly average of 6.8 but 20% more than the last 4 quarters average of 4.3
GLAUKOS's equity has decreased by 15% YoY and by 4.1% QoQ
The P/S is 14% higher than the last 4 quarters average of 8.0 but 11% lower than the 5-year quarterly average of 10.2
The revenue has grown by 2.2% from the previous quarter

Efficiency

How efficient is GLAUKOS business performance
The ROIC is down by 48% since the previous quarter
The ROE has contracted by 46% from the previous quarter
GLAUKOS's ROS has decreased by 44% from the previous quarter
The return on assets has declined by 43% since the previous quarter

Dividends

What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GKOS.

Financial health

How did GLAUKOS financials performed over time
The total assets is 110% greater than the total liabilities
The quick ratio has contracted by 30% YoY but it has grown by 6% from the previous quarter
GKOS's current ratio is down by 25% year-on-year but it is up by 9% since the previous quarter
The debt is 25% lower than the equity
The debt to equity has grown by 17% YoY and by 4.2% from the previous quarter
GLAUKOS's equity has decreased by 15% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.